特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
321928

クリプトスポリジウム症:パイプライン製品の分析

Cryptosporidiosis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 30 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
クリプトスポリジウム症:パイプライン製品の分析
出版日: 2020年05月30日
発行: Global Markets Direct
ページ情報: 英文 30 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

クリプトスポリジウム症は、クリプトスポリジウムと呼ばれる微小な寄生虫によって引き起こされる急性の疾患で、症状は水様の下痢、脱水、食欲不振、体重減少、発熱、悪心・嘔吐などが挙げられます。汚染された水、動物の世話などが発病要因となります。

当レポートでは、クリプトスポリジウム症 に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

クリプトスポリジウム症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

クリプトスポリジウム症:企業で開発中の治療薬

クリプトスポリジウム症:大学/機関で研究中の治療薬

クリプトスポリジウム症:パイプライン製品の概況

  • 初期段階の製品

クリプトスポリジウム症:企業で開発中の製品

クリプトスポリジウム症:大学/機関で研究中の製品

クリプトスポリジウム症の治療薬開発に従事している企業

  • Dafra Pharma International Ltd.
  • ioGenetics, Inc.
  • Romark Laboratories, L.C.

クリプトスポリジウム症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

クリプトスポリジウム症:休止中のプロジェクト

クリプトスポリジウム症:開発が中止された製品

付録

図表

List of Tables

  • Number of Products under Development for Cryptosporidiosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Cryptosporidiosis - Pipeline by AbbVie Inc, H1 2020
  • Cryptosporidiosis - Pipeline by Aviex Technologies LLC, H1 2020
  • Cryptosporidiosis - Pipeline by ioGenetics Inc, H1 2020
  • Cryptosporidiosis - Pipeline by Novartis AG, H1 2020
  • Cryptosporidiosis - Dormant Projects, H1 2020
  • Cryptosporidiosis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Cryptosporidiosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12222IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H1 2020, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.

Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cryptosporidiosis - Overview
    • Cryptosporidiosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cryptosporidiosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cryptosporidiosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Aviex Technologies LLC
    • ioGenetics Inc
    • Novartis AG
  • Cryptosporidiosis - Drug Profiles
    • AV-0215W - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clofazimine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBAF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDU-731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cryptosporidiosis - Dormant Projects
  • Cryptosporidiosis - Discontinued Products
  • Cryptosporidiosis - Product Development Milestones
    • Featured News & Press Releases
      • Mar 14, 2018: Calibr's repurposed drug to treat non-viral diarrhea enters into a clinical trial
      • Feb 14, 2018: Novartis forms alliance to develop medicines for treating infectious diarrheal disease
      • May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.